BA
SCMP

Boston Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Boston Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-49,939
Closed -$469K – 607
2013
Q4 		$469K Buy
49,939
+15,795
+46% +$113K 0.02% 351
2013
Q3 		$213K Buy
+34,144
New +$213K 0.01% 521

Other funds holding SCMP

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Boston Advisors's SCMP Position: Q1 2014 in Review

Boston Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2014, closing a stake of 49,939 shares — an estimated $469K sold.

Boston Advisors first reported a position in SCMP in Q3 2013 and held it in 2 quarters. The position peaked at $469K in Q4 2013. 81 funds tracked by Wall St. Rank hold SCMP as of Q1 2014.

  • Boston Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Boston Advisors sold 49,939 Sucampo Pharmaceuticals, Inc. shares in Q1 2014, an estimated $469K.
  • Boston Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2013 and held it in 2 quarters.
  • Boston Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $469K in Q4 2013.
  • 81 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2014.

Based on Boston Advisors's 13F filing for Q1 2014, filed 23 Apr 2014.